40
Participants
Start Date
May 31, 2013
Primary Completion Date
May 31, 2016
Study Completion Date
June 30, 2016
DA-9701
Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
Domperidone
Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
Placebo domperidone
Placebo DA-9701
Cheol Min Shin, Seongnam-si
Seoul National University Hospital
OTHER